Symbols / CSTL
CSTL Chart
About
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 873.91M |
| Enterprise Value | 594.32M | Income | -12.24M | Sales | 343.53M |
| Book/sh | 16.02 | Cash/sh | 9.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 823 | IPO | — |
| P/E | — | Forward P/E | -23.30 | PEG | — |
| P/S | 2.54 | P/B | 1.87 | P/C | — |
| EV/EBITDA | 75.91 | EV/Sales | 1.73 | Quick Ratio | 6.12 |
| Current Ratio | 6.46 | Debt/Eq | 7.95 | LT Debt/Eq | — |
| EPS (ttm) | -0.44 | EPS next Y | -1.28 | EPS Growth | — |
| Revenue Growth | -3.20% | Earnings | 2026-02-26 | ROA | -1.72% |
| ROE | -2.70% | ROIC | — | Gross Margin | 79.94% |
| Oper. Margin | -8.19% | Profit Margin | -3.56% | Shs Outstand | 29.19M |
| Shs Float | 24.57M | Short Float | 5.94% | Short Ratio | 4.06 |
| Short Interest | — | 52W High | 44.28 | 52W Low | 14.59 |
| Beta | 1.05 | Avg Volume | 393.82K | Volume | 526.29K |
| Target Price | $48.12 | Recom | Strong_buy | Prev Close | $28.94 |
| Price | $29.94 | Change | 3.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$48.13
Mean price target
2. Current target
$29.94
Latest analyst target
3. DCF / Fair value
$17.94
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$29.94
Low
$41.00
High
$52.00
Mean
$48.13
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-26 | main | Guggenheim | Buy → Buy | $47 |
| 2026-01-12 | main | Lake Street | Buy → Buy | $52 |
| 2026-01-05 | main | Guggenheim | Buy → Buy | $43 |
| 2025-12-22 | main | Canaccord Genuity | Buy → Buy | $50 |
| 2025-12-12 | main | BTIG | Buy → Buy | $50 |
| 2025-11-05 | main | BTIG | Buy → Buy | $38 |
| 2025-11-04 | main | Baird | Outperform → Outperform | $41 |
| 2025-09-09 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-05-21 | main | Scotiabank | Sector Outperform → Sector Outperform | $40 |
| 2025-05-06 | main | Lake Street | Buy → Buy | $35 |
| 2025-05-06 | main | Canaccord Genuity | Buy → Buy | $37 |
| 2025-02-28 | main | Baird | Outperform → Outperform | $37 |
| 2025-01-02 | reit | Stephens & Co. | Overweight → Overweight | $41 |
| 2024-11-06 | main | Scotiabank | Sector Outperform → Sector Outperform | $44 |
| 2024-11-05 | main | Lake Street | Buy → Buy | $40 |
| 2024-11-05 | main | Keybanc | Overweight → Overweight | $36 |
| 2024-11-05 | main | Baird | Outperform → Outperform | $39 |
| 2024-10-29 | main | Canaccord Genuity | Buy → Buy | $42 |
| 2024-10-14 | main | BTIG | Buy → Buy | $40 |
| 2024-08-06 | reit | Stephens & Co. | Overweight → Overweight | $37 |
- Castle Biosciences (NASDAQ:CSTL) Stock Price Down 7% - Should You Sell? - MarketBeat hu, 19 Feb 2026 20
- New skin test steers severe eczema patients to faster JAK drug relief - Stock Titan hu, 19 Feb 2026 22
- AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales - Zacks Investment Research ue, 24 Feb 2026 16
- Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance hu, 19 Feb 2026 15
- Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 52% Upside with Strong Buy Ratings - DirectorsTalk Interviews Fri, 13 Feb 2026 08
- Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz Mon, 23 Feb 2026 17
- $CSTL stock is up 20% today. Here's what we see in our data. - Quiver Quantitative ue, 04 Nov 2025 08
- Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st hu, 06 Nov 2025 08
- Breakout Move: What is the PEG ratio of CSTL - July 2025 Setups & Safe Entry Point Alerts - baoquankhu1.vn ue, 24 Feb 2026 10
- Castle Biosciences to Release Fourth Quarter and Full-Year - GlobeNewswire hu, 05 Feb 2026 12
- Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 49.91% Upside Potential for Investors - DirectorsTalk Interviews Fri, 06 Feb 2026 13
- Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance Mon, 09 Feb 2026 08
- Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on Thursday - MarketBeat hu, 19 Feb 2026 07
- Castle Biosciences (CSTL) Valuation Check After Recent Share Price Volatility - simplywall.st Sat, 07 Feb 2026 08
- Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark - Finviz Wed, 18 Feb 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4017 | 158757.0 | — | Sale at price 37.82 - 39.91 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 4017 | 160732.0 | — | Sale at price 40.01 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 2 | 8124 | — | — | Stock Award(Grant) at price 0.00 per share. | STOKES FRANKLIN M. | Chief Financial Officer | — | 2026-01-12 00:00:00 | D |
| 3 | 9207 | — | — | Stock Award(Grant) at price 0.00 per share. | OELSCHLAGER KRISTEN M | Chief Operating Officer | — | 2026-01-12 00:00:00 | D |
| 4 | 9207 | — | — | Stock Award(Grant) at price 0.00 per share. | JUVENAL TOBIN W | Officer | — | 2026-01-12 00:00:00 | D |
| 5 | 62219 | — | — | Stock Award(Grant) at price 0.00 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-12 00:00:00 | D |
| 6 | 4017 | 155694.0 | — | Sale at price 38.09 - 40.10 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2026-01-06 00:00:00 | D |
| 7 | 830 | 33490.0 | — | Sale at price 40.35 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2025-12-22 00:00:00 | D |
| 8 | 14888 | 585292.0 | — | Sale at price 39.31 per share. | OELSCHLAGER KRISTEN M | Chief Operating Officer | — | 2025-12-17 00:00:00 | D |
| 9 | 509 | 20380.0 | — | Sale at price 40.04 per share. | MAETZOLD DEREK J | Chief Executive Officer | — | 2025-12-17 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 468.69K | 0.00 |
| TaxRateForCalcs | 0.15 | 0.21 | 0.03 | 0.22 |
| NormalizedEBITDA | 38.14M | -45.02M | -76.63M | -36.60M |
| TotalUnusualItems | 0.00 | 0.00 | 18.29M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 0.00 | 0.00 | 18.29M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 18.25M | -57.47M | -67.14M | -31.29M |
| ReconciledDepreciation | 16.00M | 12.33M | 10.54M | 3.41M |
| ReconciledCostOfRevenue | 55.31M | 41.66M | 29.73M | 14.37M |
| EBITDA | 38.14M | -45.02M | -58.34M | -36.60M |
| EBIT | 22.14M | -57.35M | -68.89M | -40.01M |
| NetInterestIncome | 12.34M | 10.61M | 3.95M | 67.00K |
| InterestExpense | 577.00K | 11.00K | 17.00K | 1.00K |
| InterestIncome | 12.92M | 10.62M | 3.97M | 68.00K |
| NormalizedIncome | 18.25M | -57.47M | -84.96M | -31.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 18.25M | -57.47M | -67.14M | -31.29M |
| TotalExpenses | 323.40M | 287.76M | 228.18M | 134.16M |
| TotalOperatingIncomeAsReported | 8.67M | -67.98M | -72.86M | -40.08M |
| DilutedAverageShares | 29.25M | 26.80M | 26.05M | 25.14M |
| BasicAverageShares | 27.78M | 26.80M | 26.05M | 25.14M |
| DilutedEPS | 0.62 | -2.14 | -2.58 | -1.24 |
| BasicEPS | 0.66 | -2.14 | -2.58 | -1.24 |
| DilutedNIAvailtoComStockholders | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeCommonStockholders | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncome | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeIncludingNoncontrollingInterests | 18.25M | -57.47M | -67.14M | -31.29M |
| NetIncomeContinuousOperations | 18.25M | -57.47M | -67.14M | -31.29M |
| TaxProvision | 3.32M | 101.00K | -1.77M | -8.72M |
| PretaxIncome | 21.56M | -57.37M | -68.90M | -40.01M |
| OtherIncomeExpense | 555.00K | 18.29M | ||
| OtherNonOperatingIncomeExpenses | 555.00K | |||
| SpecialIncomeCharges | 0.00 | 0.00 | 18.29M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | -18.29M | 0.00 |
| NetNonOperatingInterestIncomeExpense | 12.34M | 10.61M | 3.95M | 67.00K |
| InterestExpenseNonOperating | 577.00K | 11.00K | 17.00K | 1.00K |
| InterestIncomeNonOperating | 12.92M | 10.62M | 3.97M | 68.00K |
| OperatingIncome | 8.67M | -67.98M | -91.14M | -40.08M |
| OperatingExpense | 263.19M | 242.78M | 196.17M | 118.34M |
| DepreciationAmortizationDepletionIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| DepreciationAndAmortizationInIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| Amortization | 11.11M | 9.01M | 8.27M | 1.96M |
| AmortizationOfIntangiblesIncomeStatement | 11.11M | 9.01M | 8.27M | 1.96M |
| ResearchAndDevelopment | 52.04M | 53.62M | 44.90M | 29.65M |
| SellingGeneralAndAdministration | 200.05M | 180.15M | 143.00M | 86.74M |
| SellingAndMarketingExpense | 123.47M | 113.66M | 86.61M | |
| GeneralAndAdministrativeExpense | 76.58M | 66.50M | 56.40M | |
| OtherGandA | 76.58M | 66.50M | 56.40M | |
| GrossProfit | 271.86M | 174.81M | 105.03M | 78.26M |
| CostOfRevenue | 60.20M | 44.98M | 32.01M | 15.82M |
| TotalRevenue | 332.07M | 219.79M | 137.04M | 94.08M |
| OperatingRevenue | 332.07M | 219.79M | 137.04M | 94.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 28.48M | 27.41M | 26.55M | 25.38M |
| ShareIssued | 28.48M | 27.41M | 26.55M | 25.38M |
| TotalDebt | 26.34M | 15.34M | 13.40M | 8.20M |
| TangibleBookValue | 349.61M | 273.93M | 272.80M | 322.82M |
| InvestedCapital | 465.86M | 391.27M | 399.15M | 411.74M |
| WorkingCapital | 310.76M | 247.97M | 256.16M | 328.86M |
| NetTangibleAssets | 349.61M | 273.93M | 272.80M | 322.82M |
| CapitalLeaseObligations | 16.32M | 15.34M | 13.40M | 8.20M |
| CommonStockEquity | 455.83M | 391.27M | 399.15M | 411.74M |
| TotalCapitalization | 465.58M | 391.27M | 399.15M | 411.74M |
| TotalEquityGrossMinorityInterest | 455.83M | 391.27M | 399.15M | 411.74M |
| StockholdersEquity | 455.83M | 391.27M | 399.15M | 411.74M |
| GainsLossesNotAffectingRetainedEarnings | 230.00K | 136.00K | -381.00K | 0.00 |
| OtherEquityAdjustments | 230.00K | 136.00K | -381.00K | |
| RetainedEarnings | -200.13M | -218.37M | -160.91M | -93.77M |
| AdditionalPaidInCapital | 655.70M | 609.48M | 560.41M | 505.48M |
| CapitalStock | 28.00K | 27.00K | 27.00K | 25.00K |
| CommonStock | 28.00K | 27.00K | 27.00K | 25.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 75.40M | 62.07M | 48.18M | 50.83M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.01M | 14.40M | 12.05M | 25.95M |
| OtherNonCurrentLiabilities | 18.29M | |||
| NonCurrentDeferredLiabilities | 1.61M | 206.00K | 428.00K | 635.00K |
| NonCurrentDeferredRevenue | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 1.61M | 206.00K | 428.00K | 635.00K |
| LongTermDebtAndCapitalLeaseObligation | 24.40M | 14.20M | 11.62M | 7.02M |
| LongTermCapitalLeaseObligation | 14.66M | 14.20M | 11.62M | 7.02M |
| LongTermDebt | 9.74M | |||
| CurrentLiabilities | 49.39M | 47.67M | 36.13M | 24.89M |
| OtherCurrentLiabilities | 774.00K | 606.00K | 415.00K | 663.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 1.94M | 1.14M | 1.78M | 1.18M |
| CurrentCapitalLeaseObligation | 1.67M | 1.14M | 1.78M | 1.18M |
| CurrentDebt | 278.00K | |||
| OtherCurrentBorrowings | 278.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 33.78M | 29.84M | 25.26M | 16.24M |
| PayablesAndAccruedExpenses | 12.89M | 16.08M | 8.68M | 6.80M |
| CurrentAccruedExpenses | 4.92M | 5.41M | 3.95M | 4.25M |
| Payables | 7.98M | 10.67M | 4.73M | 2.55M |
| TotalTaxPayable | 1.08M | 401.00K | 37.00K | 695.00K |
| AccountsPayable | 6.90M | 10.27M | 4.73M | 2.55M |
| TotalAssets | 531.24M | 453.34M | 447.33M | 462.57M |
| TotalNonCurrentAssets | 171.08M | 157.71M | 155.04M | 108.83M |
| OtherNonCurrentAssets | 1.23M | 1.44M | 1.11M | 1.72M |
| NonCurrentAccountsReceivable | 918.00K | 1.19M | 1.09M | 1.31M |
| GoodwillAndOtherIntangibleAssets | 106.23M | 117.33M | 126.35M | 88.92M |
| OtherIntangibleAssets | 95.54M | 106.64M | 115.66M | 88.92M |
| Goodwill | 10.69M | 10.69M | 10.69M | 0.00 |
| NetPPE | 62.71M | 37.74M | 26.50M | 16.88M |
| AccumulatedDepreciation | -12.83M | -8.11M | -7.85M | -3.04M |
| GrossPPE | 75.54M | 45.85M | 34.34M | 19.93M |
| Leases | 14.62M | 9.99M | 5.17M | 5.04M |
| ConstructionInProgress | 9.61M | 637.00K | 1.27M | 27.00K |
| OtherProperties | 35.22M | 28.78M | 21.90M | 11.11M |
| MachineryFurnitureEquipment | 8.85M | 6.45M | 6.00M | 3.75M |
| LandAndImprovements | 7.25M | 0.00 | ||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 360.15M | 295.63M | 292.29M | 353.74M |
| OtherCurrentAssets | 7.67M | 6.29M | 6.21M | 4.81M |
| PrepaidAssets | 4.81M | |||
| Inventory | 8.13M | 7.94M | 3.98M | 2.02M |
| Receivables | 51.22M | 38.30M | 23.48M | 17.28M |
| AccountsReceivable | 51.22M | 38.30M | 23.48M | 17.28M |
| CashCashEquivalentsAndShortTermInvestments | 293.13M | 243.10M | 258.62M | 329.63M |
| OtherShortTermInvestments | 173.42M | 144.26M | 135.68M | 0.00 |
| CashAndCashEquivalents | 119.71M | 98.84M | 122.95M | 329.63M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 36.54M | -19.25M | -47.29M | -22.47M |
| RepaymentOfDebt | -97.00K | -142.00K | -122.00K | -8.00K |
| IssuanceOfDebt | 10.00M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -28.33M | -13.62M | -5.63M | -3.48M |
| InterestPaidSupplementalData | 434.00K | 11.00K | 16.00K | 1.00K |
| IncomeTaxPaidSupplementalData | 2.50M | 198.00K | 120.00K | 16.00K |
| EndCashPosition | 119.71M | 98.84M | 122.95M | 329.63M |
| BeginningCashPosition | 98.84M | 122.95M | 329.63M | 409.85M |
| ChangesInCash | 20.87M | -24.11M | -206.69M | -80.22M |
| FinancingCashFlow | 6.14M | -2.30M | 1.51M | 5.42M |
| CashFlowFromContinuingFinancingActivities | 6.14M | -2.30M | 1.51M | 5.42M |
| NetOtherFinancingCharges | -8.76M | -5.13M | -1.69M | -1.12M |
| ProceedsFromStockOptionExercised | 5.00M | 2.98M | 3.33M | 6.55M |
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 9.90M | -142.00K | -122.00K | -8.00K |
| NetLongTermDebtIssuance | 9.90M | -142.00K | -122.00K | -8.00K |
| LongTermDebtPayments | -97.00K | -142.00K | -122.00K | -8.00K |
| LongTermDebtIssuance | 10.00M | 0.00 | 0.00 | |
| InvestingCashFlow | -50.14M | -16.18M | -166.54M | -66.66M |
| CashFlowFromContinuingInvestingActivities | -50.14M | -16.18M | -166.54M | -66.66M |
| NetOtherInvestingChanges | 547.00K | -63.18M | ||
| NetInvestmentPurchaseAndSale | -21.83M | -2.58M | -134.69M | 0.00 |
| SaleOfInvestment | 183.90M | 186.50M | 0.00 | |
| PurchaseOfInvestment | -205.73M | -189.07M | -134.69M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | -26.97M | 0.00 |
| PurchaseOfBusiness | 0.00 | 0.00 | -26.97M | 0.00 |
| NetPPEPurchaseAndSale | -28.31M | -13.61M | -5.44M | -3.47M |
| SaleOfPPE | 18.00K | 13.00K | 195.00K | 10.00K |
| PurchaseOfPPE | -28.33M | -13.62M | -5.63M | -3.48M |
| OperatingCashFlow | 64.87M | -5.63M | -41.66M | -18.98M |
| CashFlowFromContinuingOperatingActivities | 64.87M | -5.63M | -41.66M | -18.98M |
| ChangeInWorkingCapital | -14.12M | -6.63M | -7.00K | -4.10M |
| ChangeInOtherWorkingCapital | 4.59M | 8.49M | 6.21M | |
| ChangeInOtherCurrentLiabilities | -1.29M | 852.00K | -608.00K | -1.13M |
| ChangeInOtherCurrentAssets | 1.58M | -588.00K | 1.61M | 751.00K |
| ChangeInPayablesAndAccruedExpense | -442.00K | 12.43M | 8.11M | 8.31M |
| ChangeInAccruedExpense | 3.93M | 6.73M | 7.53M | 8.49M |
| ChangeInPayable | -4.37M | 5.71M | 582.00K | -182.00K |
| ChangeInAccountPayable | -4.37M | 5.71M | 582.00K | -182.00K |
| ChangeInPrepaidAssets | -1.14M | -435.00K | -1.22M | -7.73M |
| ChangeInInventory | -193.00K | -3.96M | -1.68M | 327.00K |
| ChangeInReceivables | -12.64M | -14.93M | -6.22M | -4.63M |
| ChangesInAccountReceivables | -12.64M | -14.93M | -6.22M | -4.63M |
| OtherNonCashItems | 268.00K | 635.00K | -18.13M | |
| StockBasedCompensation | 50.32M | 51.22M | 36.32M | 21.74M |
| AmortizationOfSecurities | -6.68M | -5.49M | -1.37M | 0.00 |
| DeferredTax | 1.40M | -223.00K | -1.88M | -8.74M |
| DeferredIncomeTax | 1.40M | -223.00K | -1.88M | -8.74M |
| DepreciationAmortizationDepletion | 16.00M | 12.33M | 10.54M | 3.41M |
| DepreciationAndAmortization | 16.00M | 12.33M | 10.54M | 3.41M |
| AmortizationCashFlow | 11.11M | 9.01M | 8.27M | 1.96M |
| AmortizationOfIntangibles | 11.11M | 9.01M | 8.27M | 1.96M |
| Depreciation | 4.89M | 3.32M | 2.28M | 1.45M |
| OperatingGainsLosses | -555.00K | |||
| GainLossOnInvestmentSecurities | -555.00K | |||
| NetIncomeFromContinuingOperations | 18.25M | -57.47M | -67.14M | -31.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CSTL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|